Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Belite Bio, Inc. Sponsored ADR (BLTE : NSDQ)

• Company Description    Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. Belite Bio Inc. is based in SAN DIEGO. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $159.96 Daily Weekly Monthly 20 Day Moving Average: 200,932 shares Shares Outstanding: 37.51 (millions) Market Capitalization: $6,000.84 (millions) Beta: -1.46 52 Week High: $169.75 52 Week Low: $49.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.74% 5.92% 12 Week 103.77% 100.49% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12750 HIGH BLUFF DRIVE SUITE 475 - SAN DIEGO,CA 92130 USA ph: 858-246-6240 fax: - ir@belitebio.com http://www.belitebio.com

• General Corporate Information    Officers Yu-Hsin Lin - Chief Executive Officer; Chairman of the Board Hao-Yuan Chuang - Chief Financial Officer Wan-Shan Chen - Director John M. Longo - Director Gary C. Biddle - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07782B104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/16/26 Share - Related Items Shares Outstanding: 37.51 Most Recent Split Date: (:1) Beta: -1.46 Market Capitalization: $6,000.84 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/16/26

• Fundamental Ratios P/E Current FY Estimate: 999.75 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 18.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -132.14% vs. Previous Quarter: -30.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -34.28 06/30/25 - -34.90 ROA 12/31/25 - - 09/30/25 - -33.05 06/30/25 - -33.56 Current Ratio 12/31/25 - - 09/30/25 - 34.37 06/30/25 - 23.15 Quick Ratio 12/31/25 - - 09/30/25 - 34.37 06/30/25 - 23.15 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 8.61 06/30/25 - 4.71 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©